In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Nkarta (NKTX – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $4.55.
Willey covers the Healthcare sector, focusing on stocks such as Atreca, Exelixis, and Zymeworks. According to TipRanks, Willey has an average return of 13.5% and a 46.38% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nkarta with a $24.67 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $18.48 and a one-year low of $3.12. Currently, Nkarta has an average volume of 388.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.
Read More on NKTX:
- Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
- Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
- Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
- Nkarta to Participate at Upcoming Investor Conferences
- Nkarta chief financial and business officer resigns
